HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Market News Stocks News ETF News Crypto News

Castle Biosciences, Inc.

Contributing Author

Recent Articles by Castle Biosciences, Inc.

Oct-01
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine CSTL GlobeNewswire
Sep-23
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award CSTL GlobeNewswire
Sep-17
Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 CSTL GlobeNewswire
Sep-09
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions CSTL GlobeNewswire
Aug-25
New Evidence Published Supporting Use of DecisionDx-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma CSTL GlobeNewswire
Aug-21
Castle Biosciences to Participate in Upcoming Investor Conferences CSTL GlobeNewswire
Aug-04
Castle Biosciences Reports Second Quarter 2025 Results CSTL GlobeNewswire
Jul-29
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference CSTL GlobeNewswire
Jul-25
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal CSTL GlobeNewswire
Jul-23
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test CSTL GlobeNewswire
Jul-17
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture CSTL GlobeNewswire
Jul-14
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 CSTL GlobeNewswire
Jun-19
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CSTL GlobeNewswire
Jun-16
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases CSTL GlobeNewswire
Jun-11
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention CSTL GlobeNewswire
Jun-04
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards CSTL GlobeNewswire
May-29
New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes CSTL GlobeNewswire
May-21
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference CSTL GlobeNewswire
May-09
Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result CSTL GlobeNewswire
May-07
Castle Biosciences Celebrates Skin Cancer Awareness Month CSTL GlobeNewswire
May-05
Castle Biosciences Reports First Quarter 2025 Results CSTL GlobeNewswire
May-05
Castle Biosciences to Acquire Previse CSTL GlobeNewswire
May-02
New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer CSTL GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.